First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...

First fully integrated spatial multiomic assay from 10x Genomics (TXG) brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif ...

On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer samples into high-resolution, multimodal datasets, backed by £18.9 million in ...

Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions ...

A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms In this study, "High resolution mapping ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. 10x Genomics is collaborating with PharosAI and leading UK institutions to build ...

After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...

Biological processes are framed by the context they take place in. A new tool developed by the Stegle Group from EMBL Heidelberg and the German Cancer Research Centre (DKFZ) helps put molecular ...